---
schema_version: "secwatch.filing_event.v1"
accession: "0001558370-22-008420"
form_type: "8-K"
ticker: "ALT"
cik: "0001326190"
company_name: "Altimmune, Inc."
filed_at: "2022-05-12T23:59:59+00:00"
generated_at: "2026-06-25T17:49:43.425542+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Altimmune Q1 net loss $19.4M ($0.44/share); cash $180.0M; key pemvidutide data readouts Q3/Q4 2022

## Summary
- Net loss of $19.4M ($0.44 per share) vs $14.9M ($0.38) in Q1 2021; R&D expense $15.1M.
- Cash, cash equivalents and restricted cash totaled $180.0M at March 31, 2022.
- Pemvidutide Phase 2 MOMENTUM obesity trial enrolling ~320 subjects; interim 24-week data expected Q4 2022.
- Phase 1b NAFLD trial enrollment completed; 12-week liver fat and weight loss data expected Q3 2022.
- HepTcell Phase 2 chronic hepatitis B trial continuing; data readout expected H1 2023.

## SEC filing metadata
- accession: 0001558370-22-008420
- form_type: 8-K
- ticker: ALT
- cik: 0001326190
- company_name: Altimmune, Inc.
- filed_at: 2022-05-12T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1326190/000155837022008420/0001558370-22-008420-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1326190/000155837022008420/alt-20220512x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001558370-22-008420
- JSON: https://secwatch.observer/filing/0001558370-22-008420.json
- Plain text: https://secwatch.observer/filing/0001558370-22-008420.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.